Brightlands Venture Partners
VC Fund
Geleen, The Netherlands
Brightlands Venture Partners is an independent regional venture capital fund manager in the south of the Netherlands. They are an ecosystem investor, investing in companies with a link to one of the Brightlands campuses. The management company has three funds under management: Limburg Ventures, Chemelot Ventures and Brightlands Agrifood Fund. Whilethe funds are for the larger part privately funded, we seek to complement this by financing from public sources to extend our reach.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 54%
- Fund size:
- $53M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Brightlands Venture Partners invests in
Stages Brightlands Venture Partners invests in
Countries Brightlands Venture Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Investment Focus
Industry
- Biotechnology 5 (18%)
- Health Care 4 (14%)
- Medical 3 (11%)
- Life Science 2 (7%)
- Medical Device 2 (7%)
Stage
- Seed 8 (29%)
- Series A 7 (25%)
- Funding Round 4 (14%)
- Venture - Series Unknown 4 (14%)
- Series B 3 (11%)
Country
- The Netherlands 16 (57%)
- Germany 3 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Kim de Boer
Partner
|
Partner | Total investments: 3 | Find email | |
Casper Bruens
Founder,Managing Partner & Director
|
Founder,Managing Partner & Director | Total investments: 0 | Find email | |
Marcel Kloosterman
Director
|
Director | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vertoro
|
Vertoro transforms woody and agricultural residues into a wide range of bio-based chemicals, materials, and fuels. | $11.5M / Series B / Jun 17, 2026 | |
Qorium
|
Qorium is a biotech company that leverages cell culturing and tissue engineering technology to provide premium, real leather. | $25.5M / Series A / Nov 11, 2025 | |
Novenda Technologies
|
Novenda Technologies provides multi-material 3D printing solutions for dental and medical technology applications using material jetting. | $6.1M / Series A / Jul 09, 2025 | |
Hy2Care
|
Hy2Care BV is a business start-up of the University of Twente, the Netherlands. It is Hy2Care’s ambition to introduce into the market the first cure for Osteoarthritis, the injectable hydrogel.Osteoarthritis is the 4th leading cause of mobility associated disability and affects more than 100 million patients in the Western world, who are all inneed for an effective treatment.It is the aim of Hy2Care to change the future for patients suffering from osteoarthritis. | $5M / Venture - Series Unknown / May 14, 2025 | |
Grassa
|
Grassa BV richt zich op het verwaarden van plantaardige stromen door middel van bioraffinage. Grassa haalt veel méér uit gras en gewas: hoogwaardige, eiwitrijke veevoeding én een goede bestemming voor de reststromen. Met een mobiele raffinagemachine verwerkt Grassa bijvoorbeeld vers gras vanaf de weide, reststromen uit de tuinbouw, woekerendewaterplanten uit de rivieren of natuurgras uit natuurgebieden. Na raffinage komen vier producten vrij: vezels, eiwit, fosfaat en ‘wei’ (sap). | $3.9M / Mar 19, 2025 | |
PL BioScience
|
STEM CELL EXPANSION IN SAFE AND REPRODUCIBLE CONDITIONS. We deliver advanced 2D and 3D cell culture solutions based on human Platelet Lysate – for basic research, cellular therapeutics and clinical applications. Choose between different safety grades meeting your needs: Research Grade, GMP Grade or GMP-Clinical Grade. | $8.5M / Series A / Aug 08, 2024 | |
Vivalyx
|
Vivalyx Omnisol will be a process- and cost-effective one-stop solution for all preservation applications, allowing NMP without the use of blood or human products. | $5.8M / Seed / Apr 30, 2024 | |
|
Qorium
|
Qorium is a biotech company that leverages cell culturing and tissue engineering technology to provide premium, real leather. | Seed / Jan 10, 2024 | |
Matisse Pharmaceuticals
|
Matisse Pharmaceuticals is a biotechnology company dedicated to development of pharmaceutical therapies to treat disorders that are associated with fulminant inflammation such as sepsis. The most advanced product in development is the heparin fraction M6229 for the treatment of severe sepsis and septic shock. | $3.9M / Venture - Series Unknown / Jan 04, 2024 | |
Corporis Medical
|
Corporis Medical is a young medical device company. They develop and commercialize innovative medical devices. They also lower the costs associated with surgery and surgical procedures for surgeons. They improve access, closure and diagnostic measurements. | $4.3M / Series B / Dec 07, 2023 | |
| See all 28 investments → | |||
Co-Investors
NV Industriebank LIOF
7 deals together
LIOF
4 deals together
Fransen Gerrits
3 deals together
Lumana Invest
3 deals together
SHIFT Invest
3 deals together
4impact
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Brightlands Venture Partners invest in?
Brightlands Venture Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 28 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Brightlands Venture Partners?
Public channels for Brightlands Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Brightlands Venture Partners?
The team at Brightlands Venture Partners includes Kim de Boer (Partner), Casper Bruens (Founder,Managing Partner & Director) and Marcel Kloosterman (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
